AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca (AZN) reported overall survival (OS) data from a late-stage study, which evaluated its partner Daiichi Sankyo’s investigational candidate, datopotamab deruxtecan (Dato-DXd), compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Docetaxel is the current standard-of-care chemotherapy for this patient population.Though the OS results numerically favored Dato-DXd, it failed to achieve statistical significance in the overall population of the phas ...